Florokinolonlara Direnç Mekanizmaları
Özet
Florokokinolonlar son yıllarda oldukça yaygın kullanılan geniş spektrumlu antibiyotiklerdir. Ancak geniş enfeksiyon yelpazesinde gelişigüzel ve sık kullanılması sonucu florokinolonlara direnç karşımıza çıkmaktadır. Florokinolonların bakterilerdeki hedefleri DNA giraz ve Topoziomeraz IV enzimleridir. Florokinolonlar gram pozitif ve negatif bakterilerdeki hedef enzimlerine bağlanarak bakteri DNA sentezini durdururlar ve bakterisid etki yaparlar. DNA giraz ve Topoizomeraz IV’ü kodlayan genlerdeki mutasyonlar florokinolon direncinin ilk nedenlerindendir. Ancak farklı mekanizmalarla da direnç gelişimi olmaktadır.
Referanslar
Jacoby GA. Mechanisms of resistance to quinolones. Clinical infectious dieases. 2005;41(2): 120–126. doi: 10.1086/428052
Ashley RE, Dittmore A, McPherson SA, Turnbough CL, Neuman KC, Osheroff N. Activities of gyrase and topoisomerase IV on positively supercoiled DNA. Nucleic Acids Research. 2017;45(16): 9611-9624. doi: 10.1093/nar/gkx649
Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews. 1997;61(3): 377-392. doi: 10.1128/mmbr.61.3.377-392.1997
Ince D, Zhang X, Silver LC, Hooper DC. Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrobial Agents and Chemotherapy. 2002;46(11): 3370-3380. doi: 10.1128/AAC.46.11.3370-3380.2002
Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Annals of the New York academy of sciences, 2015, 1354(1): 12-31. doi: 10.1111/nyas.12830
Chiu CH, Lee HY, Tseng LY, Chen CL, Chia JH, Su LH, et al.Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactamand imipenem in Acinetobacter baumannii clinical isolates inTaiwan. International Journal of Antimicrobial Agents. 2010;35(4): 382–386. doi: 10.1016/j.ijantimicag.2009.12.009
Agnello M, Wong-Beringer A. Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PLoSOne. 2012;7(8):e42973. doi: 10.1371/journal.pone.0042973
Tessier PR, Nicolau DP. In vitro activity of novel gyrase inhibitors against a highly resistant population of Pseudomonas aeruginosa. Antimicrobial Agents Chemotherapy. 2013;57(6): 2887–2889. doi: 10.1128/AAC.01740-12
Ruiz J. Mechanisms of resistance to quinolones: target alterations,decreased accumulation and DNA gyrase protection. Journal of Antimicrobial Chemotherapy. 2003;51(5): 1109–1117. doi: 10.1093/jac/dkg222
Bryan DS, Joseph ALB, Glenn WK. Fluoroquinolone resistance in bacteria. Douglas LM (Ed). Antimicrobial Drug Resistance_ Mechanisms of Drug Resistance. 2nd ed..Springer; 2017.
Sandra GS, María FV, María JOP, Ana BLB, Diego AÁ and Rosalino V. Mechanisms of Resistance to Quinolones. Mihai M (ed). Antimicobial Resistance. İntechOpen; 2021. doi: 10.5772/intecgopen.872316
Hasdemir U. The role of cell wall organization and active efflux pump systems in multidrug resistance of bacteria. Mikrobiyoloji Bülteni. 2007 Apr;41(2): 309-327.
Costa SS, Sobkowiak B, Parreira R, Edgeworth JD, Viveiros M, Clark TG, et al. Genetic diversity of norA, coding for a main efflux pump of Staphylococcus aureus. Frontiers in Genetics. 2019;9: 710. doi: 10.3389/fgene.2018.00710
Truong-Bolduc QC, Strahilevitz J, Hooper DC. NorC, a newefflux pump regulated by MgrA of Staphylococcus aureus. Antimicrobial Agents Chemotherapy. 2006;50(3): 1104–1107. doi: 10.1128/AAC.50.3.1104-1107.2006
Huang J, O’Toole PW, Shen W, Amrine-Madsen H, Jiang X, LoboN, et al. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrobial Agents Chemotherapy. 2004;48(3): 909–917. doi:10.1128/AAC.48.3.909-917.2004
Yamada Y, Hideka KI, Shiota S et al. Gene cloning and characterization of SdrM, a chromosomally-encoded multidrug efflux pump, from Staphylococcus aureus. Biological and Pharmaceutical Bulletin, 2006:29.3; 554-556. doi: 10.1248/bpb.29.554
Blair JM, Richmond GE, Piddock LJ. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future microbiology. 2014:9(10); 1165-1177. doi: 10.2217/fmb.14.66
Nikaido H. Structure and mechanism of RND-type multidrug efflux pumps. Advances in Enzymology and Related Areas of Molecular Biology. 2011: 77(1): 1. doi: 10.1002/9780470920541.ch1
Anes J, McCusker MP, Fanning S, Martins M. The ins and outs of RND efflux pumps in Escherichia coli. Frontiers in Microbiology. 2015;6:587. doi: 10.3389/fmicb.2015.00587
Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-negative bacteria: Molecular mechanism and inhibition. Frontiers in Microbiology. 2015;6: 377. doi: 10.3389/fmicb.2015.00377
Martin RG, Rosner JL. Genomics of the marA/soxS/rob regulon ofEscherichia coli: identification of directly activated promoters byapplication of molecular genetics and informatics to microarraydata. Molecular Microbiology. 2002;44(6): 1611–1624. doi: 10.1046/j.1365-2958.2002.02985.x
Strateva T, Yordanov D. Pseudomonas aeruginosa—a phenomenon of bacterial resistance. Journal of Medical Microbiology. 2009;58(Pt 9): 1133–1148.
Yao H, Shen Z, Wang Y, Deng F, Liu D, Naren G, et al. Emergence of a potent multidrug efflux pump variant that enhances Campylobacter resistance to multiple antibiotics. MBio. 2016;7(5): e01543-16. doi:10.1128/mBio.01543-16
Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrobial Agents and Chemotherapy. 2011;55: 947-953. doi: 10.1128/AAC.01388-10
Zhang L, Li XZ, Poole K. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy. 2001;45(12): 3497-3503. doi: 10.1128/AAC.45.12.3497-3503.2001
Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet. 1998;351(9105): 797-799. doi: 10.1016/S0140-6736(97)07322-4
Yamane K, Wachino J, Suzuki S, et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrobial Agents Chemotherapy 2007;51(9): 3354-3360. doi: 10.1128/AAC.00339-07
Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nature Medicine 2006;12(1): 83-88. doi: 10.1038/nm1347
Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrobial Agents Chemotherapy. 2004;48(2): 596–601. doi: 10.1128/AAC.48.2.596-601.2004
Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004;64: 159-204. doi: 10.2165/00003495-200464020-00004
Hegde SS, Vetting MW, Roderick SL, Mitchenall LA, Maxwell A,Takiff HE, et al. A fluoroquinolone resistance protein fromMycobacterium tuberculosis that mimics DNA. Science. 2005;308(5727): 1480-1483. doi: 10.1126/science.1110699
Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrobial Agents Chemotherapy. 2004;48(8): 3175–3178. doi: 10.1128/AAC.48.8.3175.2004
